Drugs / T521
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04898283 | May 2021 → Oct 2026 expected | allergic asthma, allergic rhinitis | Inmunotek S.L. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04898283 ↗ |
| Route | Subcutaneous | “10,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy” NCT04898283 ↗ |